You are here

We are astonished at the current lack of attention to osteoarthritis”. Correo Farmacéutico interviews Josep Escaich

21 Oct 2011

The general manager of Bioiberica highlighted his company’s commitment to a comprehensive approach to the treatment of osteoarthritis: prevention, chondroprotector drugs, and personalized medicine. Together, all these elements improve the patients’ quality of life.

Correo Farmacéutico devoted his weekly "Companies" section to Bioibérica. In an interview given to this specialized newspaper, Josep Escaich, Bioiberica´s general director, analyzed the current crisis in the pharmaceutical sector and highlighted the need of searching for new opportunities and to adapt ourselves to the new rules of play. Moreover, Escaich defended Bioiberica Farma’s comprehensive approach to osteoarthritis as the right strategy to improve the patients’ quality of life.

For further information, go to:

Related News

16 Oct 2023

We participated in CPHI 2023 in Barcelona, ​​where we showcased our leadership in scientific research, sustainable development and strategic partnerships for a more resilient future with our portfolio of Active Pharmaceutical and Nutraceutical Ingredients.

4 May 2023

They've set up Biovall Heparin Science, a joint pharmaceutical innovation project with an investment of 25 million euros and 20 skilled jobs

28 Apr 2023

Join Bioiberica at stand F130 in Geneva, 9-11 May to discover the company’s latest science and insights driving innovation in the nutraceuticals market.